Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...

Sandoz Group Ltd ( (CH:SDZ) ) just unveiled an update. Sandoz has announced a potential acquisition of Just-Evotec Biologics’ activities in Toulouse, France, aiming to enhance its biosimilar ...

AgreementEvotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site 30.07.2025 / 07:16 CET/CESTThe issuer is solely responsible for the ...

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of three public ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Patent thickets hinder biosimilar access, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

In Q2, the FDA approved two biosimilars in the ustekinumab and bevacizumab markets and four biosimilars were launched within ...

Health plans should directly contract with drug manufacturers to provide medications at transparent and affordable prices, ...

Tiffany E Jiang , Reshma Ramachandran , and Joshua J Skydel argue that US requirements for interchangeability are not supported by evidence and hamper use of biosimilars Biological medicines ...